Vertex Pharmaceuticals (VRTX) Other financing activities (2009 - 2026)

Vertex Pharmaceuticals' Other financing activities history runs 18 years deep, the most recent figure standing at -$400000.0 for Q1 2026.

• In Q1 2026, Other financing activities fell 102.4% year-over-year to -$400000.0; the TTM figure through Mar 2026 stood at -$13.4 million (down 111.71% YoY), while the FY2025 annual figure was $3.7 million, down 96.77% from the prior year.
• Other financing activities for Q1 2026 stood at -$400000.0, down from $1.1 million in the prior quarter.
• The five-year high for Other financing activities was $109.3 million in Q4 2024, with the low at -$131.2 million in Q4 2022.
• The 5-year median for Other financing activities is $1.1 million (2023), against an average of $7.2 million.
• The sharpest annual moves came in 2023 and 2024: Other financing activities tumbled 289.89% in 2023, then jumped 7386.67% in 2024.
• Vertex Pharmaceuticals' Other financing activities stood at -$131.2 million in 2022, then surged by 98.86% to -$1.5 million in 2023, then surged by 7386.67% to $109.3 million in 2024, then plunged by 98.99% to $1.1 million in 2025, then sank by 136.36% to -$400000.0 in 2026.
• Business Quant data shows VRTX's Other financing activities at -$400000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.